Crealta Pharmaceuticals LLC, of Glendale, Wis., said the Journal of Clinical Rheumatology published a comprehensive review of a posthoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized phase III trials and one open-label extension trial.